| Ashley Anne Crum, | |
|
2380 N 400 E, North Logan, UT 84341-6000 | |
| (435) 713-9700 | |
| Not Available |
| Full Name | Ashley Anne Crum |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 11 Years |
| Location | 2380 N 400 E, North Logan, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245673946 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD2016-0081 (New Mexico) | Secondary |
| 207P00000X | Emergency Medicine | 6763480-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham City Community Hospital | Brigham city, UT | Hospital |
| Cache Valley Hospital | North logan, UT | Hospital |
| Ogden Regional Medical Center | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Integrated Care Llc | 4284548116 | 170 |
| Alpine Management And Consulting | 5496659245 | 24 |
News Archive
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
The general public are worryingly ignorant about the symptoms and risk factors that contribute to serious medical conditions such as stroke and HIV/AIDS, according to a study published in the online open access journal BMC Medicine.
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
› Verified 3 days ago
| Entity Name | Emergency Physicians Integrated Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578598199 PECOS PAC ID: 4284548116 Enrollment ID: O20031115000013 |
News Archive
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
The general public are worryingly ignorant about the symptoms and risk factors that contribute to serious medical conditions such as stroke and HIV/AIDS, according to a study published in the online open access journal BMC Medicine.
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
› Verified 3 days ago
| Entity Name | Alpine Management And Consulting |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427184449 PECOS PAC ID: 5496659245 Enrollment ID: O20031122000068 |
News Archive
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
The general public are worryingly ignorant about the symptoms and risk factors that contribute to serious medical conditions such as stroke and HIV/AIDS, according to a study published in the online open access journal BMC Medicine.
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Anne Crum, Po Box 96398, Oklahoma City, OK 73143-6398 Ph: (800) 962-3303 | Ashley Anne Crum, 2380 N 400 E, North Logan, UT 84341-6000 Ph: (435) 713-9700 |
News Archive
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
The general public are worryingly ignorant about the symptoms and risk factors that contribute to serious medical conditions such as stroke and HIV/AIDS, according to a study published in the online open access journal BMC Medicine.
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
› Verified 3 days ago